Database→ARA-290

Tier 2NeuroprotectionAnti-inflammatoryTissue RepairPREMIUM

ARA-290

ARA-290 (Cibinetide) — Innate Repair Receptor Agonist

Investigational. No FDA or EMA approval. FDA Fast Track designation and Orphan Drug designation for sarcoidosis-associated neuropathic pain (held by Araim Pharmaceuticals). EU Orphan Medicinal Product designation for sarcoidosis and islet transplantation. Araim Pharmaceuticals, the original developer, has closed. No active IND exists as of May 2026. No active clinical trials registered on ClinicalTrials.gov. Phase 3 would require a new sponsor to initiate an entirely new development program. The regulatory designations reflect the quality of Phase 2b evidence; they do not represent an active development pathway.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

ARA-290 (cibinetide) is an 11 amino acid synthetic peptide derived from the helix-B surface domain of erythropoietin. It is the only compound in this research series to have demonstrated structural nerve regeneration in a properly controlled human trial: a 23% increase in corneal nerve fiber area (CNFA) in a pre-specified primary endpoint in a double-blind Phase 2b RCT (Culver et al., 2017, IOVS). The original developer, Araim Pharmaceuticals, has closed. No active IND or clinical trial program exists as of May 2026. The Phase 2b evidence is real and unrefuted. The development pathway does not currently exist.

🔒

Full Profile: Premium Members Only

The complete ARA-290 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use